US-based ResMed has introduced its Astral 100 and Astral 150 life support ventilators in select European and Asia-Pacific markets for patients with neuromuscular disease, chronic obstructive pulmonary disease, and other adult and childhood breathing disorders.
ResMed’s Astral 100 is an entry-level model in the new generation of the company’s portable, lightweight and user-friendly life support ventilators.
The life support ventilator has excellent leak compensation and a single valve circuit system with one integrated QuickConnect tube and leak circuit options. It can be used non-invasively or invasively with a mask, mouthpiece, or tracheostomy.
Astral 150 is a more versatile solution that builds upon the features of Astral 100 by adding a double-circuit system to more accurately measure a patient’s exhaled breath in real-time and the ability to monitor the actual percentage of enriched oxygen used by a patient.
Astral 150 also includes manual breath and sigh features to mimic natural breathing patterns. It includes an option to configure up to four ventilation programs that can be set to meet a patient’s changing daily requirements.
ResMed has recently won the Red Dot Product Design Award for 2014 for its Astral 150 life support ventilator.
According to ResMed, the Astral 100 and Astral 150 life support ventilators offer an eight-hour internal battery and a weight of only 3.2kg. Two optional eight-hour external batteries provide a total run-time of 24 hours.
ResMed Respiratory Care strategic business unit president Geoff Neilson said the Astral family of life support ventilators was developed according to feedback.
"We listened to patients, physicians, and providers, and addressed their pain points related to ventilator mobility; Astral is a solution that maximises mobility and functionality," Neilson said.
Astral ventilators feature large, intuitive, easy-to-read touchscreen display and with real-time pressure and flow data for a comprehensive picture of a patient’s condition.
The touchscreen functionality can be accessed without removing the device from its mobility bag for patients taking advantage of the ventilator’s enhanced portability.
These two ventilators feature eight customisable breathing modes to ensure that patients receive optimal treatment to manage their specific respiratory requirements.
Depending on patient need, therapies can be adjusted so that patients can gradually be weaned-off the ventilator after a period of time, if appropriate.
Pending US Food and Drug Administration approval, the Astral 100 and Astral 150 life support ventilators are expected to be available in the US in later 2014.
Image: ResMed’s Astral 150 life support ventilator. Photo: courtesy of PRNewswire/ResMed.